# A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

> **NCT04540900** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Krystal Biotech, Inc.** · enrollment: 85 (actual)

## Conditions studied

- Skin Roughness
- Wrinkle
- Fine Lines
- Skin Thickness

## Interventions

- **BIOLOGICAL:** KB301
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04540900
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-07
- **Primary completion:** 2024-10-16
- **Final completion:** 2029-05-31
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540900, "A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04540900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*